Cargando…

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy

Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches to ameliorate various pathological conditions. However, in vivo studies validating the effectiveness of a short ASO (<10-mer) in the context of a human disease have not been performed. One dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keil, Jeffrey M, Seo, Joonbae, Howell, Matthew D, Hsu, Walter H, Singh, Ravindra N, DiDonato, Christine J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121513/ https://www.ncbi.nlm.nih.gov/pubmed/25004100 http://dx.doi.org/10.1038/mtna.2014.23

Ejemplares similares

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy
por: Ottesen, Eric W., et al.
Publicado: (2016)

Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
por: Sintusek, Palittiya, et al.
Publicado: (2016)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
por: Müschen, Lars Hendrik, et al.
Publicado: (2021)

A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity of Splice Isoforms of Spinal Muscular Atrophy Genes
por: Singh, Natalia N., et al.
Publicado: (2012)

Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene
por: Seo, Joonbae, et al.
Publicado: (2016)

TIA1 is a gender-specific disease modifier of a mild mouse model of spinal muscular atrophy
por: Howell, Matthew D., et al.
Publicado: (2017)

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
por: Catapano, Francesco, et al.
Publicado: (2016)

Antisense-based therapy for the treatment of spinal muscular atrophy
por: Rigo, Frank, et al.
Publicado: (2012)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

Comment on: “Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy” by Zhou et al.
por: Chen, Tai‐Heng
Publicado: (2020)

High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
por: Wijaya, Yogik Onky Silvana, et al.
Publicado: (2022)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

Dysphagia Phenotypes in Spinal Muscular Atrophy: The Past, Present, and Promise for the Future
por: McGrattan, Katlyn Elizabeth, et al.
Publicado: (2021)

In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy
por: Ojala, Kristine S., et al.
Publicado: (2021)

Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy
por: Ottesen, Eric W, et al.
Publicado: (2023)

Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
por: Mitrpant, Chalermchai, et al.
Publicado: (2013)

Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice
por: Strathmann, Eike A., et al.
Publicado: (2018)

The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
por: Zhou, Haiyan, et al.
Publicado: (2020)

Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy
por: Hammond, Suzan M., et al.
Publicado: (2022)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Advances and limitations for the treatment of spinal muscular atrophy
por: Day, John W., et al.
Publicado: (2022)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy
por: Powis, Rachael A., et al.
Publicado: (2016)

Bicalutamide and Trehalose Ameliorate Spinal and Bulbar Muscular Atrophy Pathology in Mice
por: Galbiati, Mariarita, et al.
Publicado: (2023)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy
por: Rossoll, Wilfried, et al.
Publicado: (2022)

Structural Context of a Critical Exon of Spinal Muscular Atrophy Gene
por: Singh, Natalia N., et al.
Publicado: (2022)

Patient‐identified impact of symptoms in spinal and bulbar muscular atrophy
por: Guber, Robert D., et al.
Publicado: (2017)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
por: Scaglioni, Dominic, et al.
Publicado: (2021)

Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice
por: Walter, Lisa M, et al.
Publicado: (2018)

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2017)

Disease burden of spinal muscular atrophy in Germany
por: Klug, Constanze, et al.
Publicado: (2016)

The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
por: Singh, Ravindra N, et al.
Publicado: (2020)

Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy
por: Walsh, Melissa B., et al.
Publicado: (2020)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_52nc19pmo82kpe5jb2i0de6cak